The Asian, healthcare-focused private equity investor CBC Group says its strategy of building and backing biotech companies from scratch is driving better returns amid growing investor interest in the sector.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
